CCL20 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), CCL20 upregulation by METTL3 promoted infiltration of several immunosuppressive cells including MDSCs to impair the sensitivity of tumors to anti-PD-1 immunotherapy [26].